benazepril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 299 86541-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benazepril
  • cibacen
  • benazepril hydrochloride
  • benazepril HCl
prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion
  • Molecular weight: 424.50
  • Formula: C24H28N2O5
  • CLOGP: 1.82
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.61
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 78 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.13 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 18 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.335 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.155 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 10.765 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 8.610 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 3.170 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 7.340 % High 1
herg hERG pIC50 4.405 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 41.976 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 66.374 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 3.350 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1 25
kinase-selectivity-class AXL,BRAF,GRK2,PDK4 4
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.467 High 1
mh-clint Mouse hepatocyte intrinsic clearance 51.523 High 1
mppb Mouse plasma protein binding (% unbound) 3.820 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 9.908 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 5.300 % High 1
rh-clint Rat hepatocyte intrinsic clearance 101.158 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 65.580 % High 1
rppb Rat plasma protein binding (% unbound) 4.310 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 933.254 uM High 1

Approvals:

DateAgencyCompanyOrphan
June 25, 1991 FDA US PHARMS HOLDINGS I

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebrovascular accident 148.70 12.73 154 18580 123379 90486334
Myocardial infarction 145.70 12.73 142 18592 105830 90503883
Angioedema 139.39 12.73 112 18622 64764 90544949
Cardiac failure congestive 135.21 12.73 132 18602 98562 90511151
Coronary artery disease 132.44 12.73 84 18650 33539 90576174
Off label use 80.78 12.73 66 18668 1102186 89507527
Completed suicide 61.83 12.73 109 18625 144949 90464764
Maternal exposure during pregnancy 56.06 12.73 5 18729 360058 90249655
Renal failure 52.70 12.73 96 18638 130911 90478802
Infusion related reaction 50.65 12.73 12 18722 416768 90192945
Hand deformity 49.30 12.73 3 18731 296359 90313354
Glossodynia 48.68 12.73 5 18729 321774 90287939
Transient ischaemic attack 48.62 12.73 52 18682 43124 90566589
Contraindicated product administered 48.36 12.73 5 18729 320134 90289579
Systemic lupus erythematosus 46.87 12.73 9 18725 361887 90247826
Treatment failure 45.26 12.73 5 18729 303923 90305790
Drug intolerance 45.20 12.73 18 18716 447573 90162140
Drug ineffective 41.09 12.73 148 18586 1384150 89225563
Dizziness 39.61 12.73 232 18502 589052 90020661
Blood pressure inadequately controlled 38.94 12.73 21 18713 6203 90603510
Pericarditis 38.85 12.73 5 18729 270146 90339567
Mitral valve incompetence 38.28 12.73 34 18700 22490 90587223
Wound 38.25 12.73 8 18726 302972 90306741
Swollen tongue 37.69 12.73 47 18687 45909 90563804
Product complaint 37.09 12.73 27 18707 13473 90596240
Chest pain 36.80 12.73 147 18587 319498 90290215
Angina unstable 36.24 12.73 21 18713 7122 90602591
Carotid artery stenosis 36.20 12.73 19 18715 5315 90604398
Rhabdomyolysis 35.15 12.73 48 18686 51208 90558505
Arteriosclerosis 35.14 12.73 24 18710 10829 90598884
Nephrosclerosis 35.11 12.73 12 18722 1157 90608556
Vasodilatation 33.98 12.73 15 18719 2869 90606844
Oropharyngeal swelling 33.62 12.73 11 18723 927 90608786
Renal tubular atrophy 33.60 12.73 11 18723 929 90608784
Oedema peripheral 33.27 12.73 123 18611 257792 90351921
Cardiac disorder 32.74 12.73 49 18685 56823 90552890
Emotional distress 32.50 12.73 39 18695 36623 90573090
Dehydration 32.35 12.73 101 18633 194346 90415367
Exposure during pregnancy 30.70 12.73 6 18728 238404 90371309
Blood pressure increased 28.81 12.73 98 18636 197119 90412594
Cardiovascular disorder 28.33 12.73 23 18711 13469 90596244
Gastrointestinal haemorrhage 27.63 12.73 59 18675 90189 90519524
Acute kidney injury 27.50 12.73 135 18599 320252 90289461
Renal injury 27.04 12.73 20 18714 10223 90599490
C-reactive protein increased 26.95 12.73 3 18731 181386 90428327
Tricuspid valve incompetence 25.96 12.73 24 18710 16707 90593006
Distributive shock 25.55 12.73 13 18721 3411 90606302
Palpitations 25.54 12.73 74 18660 136654 90473059
Ill-defined disorder 25.22 12.73 4 18730 184887 90424826
Joint swelling 24.97 12.73 41 18693 503259 90106454
Stomatitis 24.67 12.73 13 18721 274685 90335028
Kidney fibrosis 24.34 12.73 11 18723 2223 90607490
Fear 24.17 12.73 23 18711 16599 90593114
Arteriosclerosis coronary artery 23.68 12.73 18 18716 9585 90600128
Reaction to excipient 22.97 12.73 10 18724 1850 90607863
Kounis syndrome 22.94 12.73 11 18723 2542 90607171
Blood glucose increased 21.22 12.73 55 18679 95191 90514522
Syncope 21.22 12.73 68 18666 132595 90477118
Coronary artery occlusion 21.02 12.73 16 18718 8538 90601175
Atrial fibrillation 20.93 12.73 68 18666 133543 90476170
Myalgia 20.49 12.73 81 18653 175044 90434669
Arrhythmia 19.57 12.73 33 18701 42299 90567414
Mental status changes 19.56 12.73 34 18700 44645 90565068
General physical health deterioration 19.46 12.73 27 18707 355088 90254625
Swelling face 19.19 12.73 48 18686 81304 90528409
Product use issue 19.19 12.73 24 18710 329895 90279818
Urinary tract infection 18.98 12.73 118 18616 305514 90304199
Liver injury 18.66 12.73 6 18728 170561 90439152
Blood urea increased 18.65 12.73 27 18707 30386 90579327
Nausea 18.53 12.73 327 18407 1109989 89499724
Shock 18.31 12.73 26 18708 28752 90580961
Haemorrhoids 18.29 12.73 25 18709 26677 90583036
Hyperlipidaemia 18.09 12.73 23 18711 22893 90586820
Alopecia 18.08 12.73 48 18686 495023 90114690
Peripheral vascular disorder 17.98 12.73 13 18721 6418 90603295
Gastrointestinal disorder 17.92 12.73 16 18718 256671 90353042
Tendon rupture 17.82 12.73 15 18719 9228 90600485
Keratoacanthoma 17.41 12.73 6 18728 593 90609120
Laryngeal pain 17.28 12.73 11 18723 4411 90605302
Hyperdynamic left ventricle 17.11 12.73 5 18729 289 90609424
Anhedonia 16.97 12.73 16 18718 11415 90598298
Musculoskeletal stiffness 16.80 12.73 22 18712 296510 90313203
Depression 16.79 12.73 113 18621 300488 90309225
Cardiomegaly 16.55 12.73 20 18714 18905 90590808
Hiatus hernia 16.26 12.73 23 18711 25338 90584375
Vasoplegia syndrome 16.24 12.73 9 18725 2805 90606908
Psoriatic arthropathy 16.21 12.73 14 18720 228321 90381392
Myocardial ischaemia 16.19 12.73 17 18717 13797 90595916
Discomfort 15.90 12.73 20 18714 274315 90335398
Irritable bowel syndrome 15.63 12.73 12 18722 207436 90402277
Pyrexia 15.52 12.73 77 18657 660408 89949305
Fibromyalgia 15.45 12.73 12 18722 206257 90403456
Feeling abnormal 15.43 12.73 72 18662 167163 90442550
Arthropathy 15.35 12.73 33 18701 366209 90243504
Therapeutic product effect decreased 15.31 12.73 21 18713 277550 90332163
Asthenia 15.25 12.73 173 18561 533578 90076135
Therapeutic product effect incomplete 14.88 12.73 11 18723 193885 90415828
Infection 14.87 12.73 33 18701 362061 90247652
Tubulointerstitial nephritis 14.82 12.73 22 18712 25321 90584392
Gastritis 14.79 12.73 29 18705 41724 90567989
Hepatic enzyme increased 14.71 12.73 33 18701 360703 90249010
Ventricular hypertrophy 14.68 12.73 9 18725 3382 90606331
Blood glucose decreased 14.66 12.73 21 18713 23408 90586305
Intentional product use issue 14.57 12.73 14 18720 216878 90392835
Joint range of motion decreased 14.43 12.73 5 18729 135638 90474075
Hypotension 14.00 12.73 115 18619 325282 90284431
Chronic obstructive pulmonary disease 13.82 12.73 40 18694 73789 90535924
Nasopharyngitis 13.72 12.73 41 18693 407063 90202650
Intervertebral disc protrusion 13.65 12.73 22 18712 27174 90582539
Anxiety 13.61 12.73 110 18624 309662 90300051
Lung disorder 13.59 12.73 7 18727 149876 90459837
Amyloid related imaging abnormalities 13.58 12.73 3 18731 55 90609658
Swelling 13.56 12.73 43 18691 419015 90190698
Dysgeusia 13.44 12.73 32 18702 52528 90557185
Rheumatoid arthritis 13.35 12.73 35 18699 362579 90247134
Urinary incontinence 13.19 12.73 26 18708 37540 90572173

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 224.74 13.70 155 14673 42322 42564185
Myocardial infarction 146.13 13.70 197 14631 123812 42482695
Coronary artery disease 109.33 13.70 113 14715 53607 42552900
Cardiac failure congestive 85.84 13.70 126 14702 85476 42521031
Off label use 80.57 13.70 63 14765 638272 41968235
Cerebrovascular accident 72.56 13.70 125 14703 97035 42509472
Injury 35.03 13.70 41 14787 22275 42584232
Chest pain 31.16 13.70 113 14715 139417 42467090
Shock 30.79 13.70 44 14784 29077 42577430
Oropharyngeal oedema 30.38 13.70 7 14821 90 42606417
Product complaint 29.65 13.70 21 14807 5956 42600551
Blood glucose increased 29.10 13.70 73 14755 73626 42532881
Emotional distress 27.68 13.70 31 14797 16062 42590445
Swollen tongue 26.86 13.70 35 14793 21196 42585311
Nodular rash 23.80 13.70 6 14822 115 42606392
Asthenia 22.61 13.70 171 14657 280622 42325885
Neutropenia 22.19 13.70 22 14806 199409 42407098
Distributive shock 20.39 13.70 12 14816 2484 42604023
Lymphomatoid papulosis 19.68 13.70 6 14822 236 42606271
Angina unstable 19.59 13.70 22 14806 11426 42595081
Acute myocardial infarction 19.28 13.70 54 14774 58111 42548396
Nephrogenic systemic fibrosis 19.00 13.70 13 14815 3488 42603019
Blood pressure inadequately controlled 18.85 13.70 12 14816 2856 42603651
Depression 18.29 13.70 82 14746 111281 42495226
Pancreatitis 18.28 13.70 44 14784 43224 42563283
BRASH syndrome 18.21 13.70 10 14818 1815 42604692
Mini-tracheostomy 17.60 13.70 3 14825 6 42606501
Hypertrophic cardiomyopathy 17.35 13.70 9 14819 1456 42605051
Blood gases abnormal 17.34 13.70 6 14822 354 42606153
Tongue oedema 17.28 13.70 12 14816 3298 42603209
Fear 16.96 13.70 20 14808 10945 42595562
Dizziness 16.90 13.70 146 14682 249108 42357399
Pharyngeal oedema 16.53 13.70 15 14813 6053 42600454
Hyperglycaemic hyperosmolar nonketotic syndrome 16.51 13.70 9 14819 1609 42604898
General physical health deterioration 16.45 13.70 17 14811 151229 42455278
Carotid artery stenosis 15.92 13.70 14 14814 5422 42601085
Product use in unapproved indication 15.66 13.70 25 14803 184431 42422076
Blood pressure increased 15.22 13.70 73 14755 101855 42504652
Hyperlipidaemia 15.14 13.70 27 14801 21489 42585018
Lacunar infarction 15.13 13.70 11 14817 3249 42603258
COVID-19 15.07 13.70 11 14817 115937 42490570
Febrile neutropenia 14.99 13.70 26 14802 185677 42420830
Hypotension 14.49 13.70 145 14683 257486 42349021
Type 2 diabetes mellitus 14.06 13.70 24 14804 18447 42588060

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 315.26 12.81 229 26337 98271 110464462
Myocardial infarction 310.86 12.81 301 26265 191782 110370951
Coronary artery disease 264.86 12.81 182 26384 71508 110491225
Cerebrovascular accident 213.90 12.81 240 26326 181044 110381689
Cardiac failure congestive 195.61 12.81 210 26356 150790 110411943
Off label use 130.91 12.81 102 26464 1500083 109062650
Angina unstable 61.29 12.81 42 26524 16390 110546343
Completed suicide 59.15 12.81 159 26407 242222 110320511
Emotional distress 57.33 12.81 62 26504 44785 110517948
Shock 54.81 12.81 66 26500 53522 110509211
Transient ischaemic attack 54.62 12.81 72 26494 63910 110498823
Chest pain 52.66 12.81 204 26362 376171 110186562
Renal failure 52.65 12.81 146 26420 226428 110336305
Drug intolerance 51.06 12.81 17 26549 406495 110156238
Product complaint 50.43 12.81 35 26531 13937 110548796
Distributive shock 48.17 12.81 25 26541 5879 110556854
Carotid artery stenosis 47.70 12.81 29 26537 9234 110553499
Cardiac disorder 46.28 12.81 73 26493 76207 110486526
Swollen tongue 45.57 12.81 64 26502 60298 110502435
Acute myocardial infarction 45.17 12.81 76 26490 83701 110479032
Infusion related reaction 44.39 12.81 18 26548 381144 110181589
Treatment failure 43.90 12.81 7 26559 277227 110285506
Maternal exposure during pregnancy 43.76 12.81 5 26561 254878 110307855
Contraindicated product administered 42.30 12.81 5 26561 248262 110314471
Blood pressure inadequately controlled 39.57 12.81 24 26542 7609 110555124
Cardiovascular disorder 39.23 12.81 37 26529 22723 110540010
Systemic lupus erythematosus 38.99 12.81 7 26559 254331 110308402
Pericarditis 38.37 12.81 4 26562 219110 110343623
Mitral valve incompetence 37.31 12.81 43 26523 33286 110529447
Fear 36.76 12.81 36 26530 23157 110539576
Drug ineffective 36.75 12.81 215 26351 1520325 109042408
Hypertrophic cardiomyopathy 33.52 12.81 16 26550 3147 110559586
C-reactive protein increased 33.39 12.81 6 26560 217913 110344820
Arteriosclerosis 32.99 12.81 35 26531 24732 110538001
Peripheral vascular disorder 32.17 12.81 22 26544 8554 110554179
Blood pressure increased 32.07 12.81 135 26431 258238 110304495
Wound 30.86 12.81 9 26557 234428 110328305
Dizziness 30.43 12.81 278 26288 697915 109864818
Blood glucose increased 30.38 12.81 85 26481 132411 110430322
Nephrosclerosis 30.23 12.81 13 26553 2008 110560725
Glossodynia 30.19 12.81 8 26558 221996 110340737
Helicobacter infection 30.16 12.81 4 26562 181873 110380860
Hyperlipidaemia 30.06 12.81 40 26526 35808 110526925
Exposure during pregnancy 29.46 12.81 3 26563 167421 110395312
Hypotension 28.34 12.81 219 26347 523630 110039103
Vasodilatation 28.11 12.81 15 26551 3729 110559004
Atrial fibrillation 27.73 12.81 119 26447 229523 110333210
Renal injury 27.72 12.81 28 26538 18685 110544048
Joint swelling 27.34 12.81 40 26526 442805 110119928
Neutropenia 27.10 12.81 30 26536 374590 110188143
Drug abuse 26.93 12.81 5 26561 177406 110385327
Gastrointestinal haemorrhage 26.70 12.81 94 26472 165424 110397309
Rheumatoid arthritis 26.41 12.81 20 26546 299593 110263140
Ventricular hypertrophy 26.25 12.81 18 26548 7027 110555706
Arrhythmia 26.07 12.81 54 26512 69521 110493212
Arteriosclerosis coronary artery 25.78 12.81 31 26535 25087 110537646
Lacunar infarction 25.67 12.81 17 26549 6269 110556464
Rhabdomyolysis 25.43 12.81 75 26491 120326 110442407
Tricuspid valve incompetence 25.39 12.81 30 26536 23843 110538890
Depression 25.20 12.81 146 26420 317189 110245544
Acute kidney injury 25.18 12.81 248 26318 635182 109927551
Pyrexia 24.96 12.81 121 26445 898144 109664589
Unevaluable event 24.62 12.81 48 26518 59179 110503554
Myocardial ischaemia 24.28 12.81 31 26535 26653 110536080
Laryngeal pain 24.02 12.81 16 26550 5959 110556774
Stomatitis 23.87 12.81 18 26548 270224 110292509
General physical health deterioration 23.80 12.81 41 26525 425254 110137479
Tongue oedema 23.69 12.81 18 26548 8238 110554495
Muscle injury 23.58 12.81 3 26563 140804 110421929
Musculoskeletal stiffness 23.02 12.81 20 26546 279802 110282931
Anhedonia 22.70 12.81 23 26543 15405 110547328
Renal tubular atrophy 22.57 12.81 11 26555 2265 110560468
Dehydration 22.45 12.81 129 26437 279382 110283351
Coronary artery occlusion 22.28 12.81 23 26543 15749 110546984
Asthenia 22.20 12.81 258 26308 688741 109873992
Oropharyngeal oedema 22.08 12.81 7 26559 458 110562275
Gastritis 21.69 12.81 43 26523 53656 110509077
Oedema peripheral 21.57 12.81 144 26422 328516 110234217
Anxiety 21.35 12.81 149 26417 344929 110217804
Palpitations 21.17 12.81 85 26481 159127 110403606
Therapeutic product effect incomplete 20.96 12.81 14 26552 223791 110338942
Product use in unapproved indication 20.85 12.81 48 26518 447329 110115404
Cardiomegaly 20.68 12.81 30 26536 29100 110533633
Ill-defined disorder 20.67 12.81 6 26560 156847 110405886
Reaction to excipient 20.56 12.81 10 26556 2049 110560684
Oropharyngeal swelling 20.47 12.81 9 26557 1465 110561268
Hyperdynamic left ventricle 20.42 12.81 7 26559 585 110562148
Psoriatic arthropathy 20.25 12.81 11 26555 196750 110365983
Cardiac arrest 20.05 12.81 97 26469 196656 110366077
Nodular rash 19.93 12.81 6 26560 330 110562403
Mini-tracheostomy 18.71 12.81 3 26563 6 110562727
Lymphomatoid papulosis 18.69 12.81 6 26560 409 110562324
Blood urea increased 18.68 12.81 41 26525 54916 110507817
Product use issue 18.41 12.81 29 26537 311666 110251067
Febrile neutropenia 18.21 12.81 30 26536 316737 110245996
Vasoplegia syndrome 18.18 12.81 13 26553 5426 110557307
Pharyngeal oedema 18.06 12.81 21 26545 16407 110546326
Cerebral infarction 17.99 12.81 39 26527 51799 110510934
Intentional product use issue 17.76 12.81 20 26546 247886 110314847
Liver disorder 17.75 12.81 6 26560 142237 110420496
Hypertensive heart disease 17.74 12.81 12 26554 4584 110558149
Ischaemic cardiomyopathy 17.73 12.81 15 26551 7996 110554737
Syncope 17.26 12.81 95 26471 202441 110360292
Kounis syndrome 17.18 12.81 13 26553 5912 110556821
Irritable bowel syndrome 17.17 12.81 9 26557 164206 110398527
Nasopharyngitis 17.04 12.81 44 26522 394317 110168416
Fibromyalgia 16.95 12.81 10 26556 170899 110391834
Kidney fibrosis 15.84 12.81 11 26555 4381 110558352
Pancreatitis 15.84 12.81 54 26512 93479 110469254
Nephrogenic systemic fibrosis 15.83 12.81 12 26554 5471 110557262
Tendon rupture 15.48 12.81 18 26548 14060 110548673
Swelling face 15.37 12.81 53 26513 92268 110470465
Cough 15.35 12.81 174 26392 461467 110101266
BRASH syndrome 15.04 12.81 10 26556 3713 110559020
Stent placement 14.90 12.81 13 26553 7221 110555512
Lip dry 14.81 12.81 3 26563 100080 110462653
Gastrointestinal disorder 14.77 12.81 22 26544 241930 110320803
Lung disorder 14.64 12.81 13 26553 180034 110382699
Liver injury 14.64 12.81 9 26557 150404 110412329
Coronary artery surgery 14.59 12.81 4 26562 157 110562576
Renal impairment 14.49 12.81 86 26480 188359 110374374
Hyperglycaemic hyperosmolar nonketotic syndrome 14.42 12.81 9 26557 3000 110559733
Peptic ulcer 14.32 12.81 13 26553 7606 110555127
Carotid artery disease 14.19 12.81 8 26558 2215 110560518
Ventricular extrasystoles 14.19 12.81 22 26544 22619 110540114
Coronary artery stenosis 14.15 12.81 17 26549 13741 110548992
Diverticulum 14.07 12.81 18 26548 15508 110547225
Alopecia 14.05 12.81 43 26523 364710 110198023
Wound infection 14.05 12.81 3 26563 96462 110466271
Neck injury 14.00 12.81 9 26557 3159 110559574
Impaired healing 13.95 12.81 16 26550 196701 110366032
Pancytopenia 13.86 12.81 18 26548 209595 110353138
Cardiomyopathy 13.72 12.81 27 26539 33498 110529235
Blood glucose decreased 13.62 12.81 25 26541 29463 110533270
Myelosuppression 13.60 12.81 3 26563 94337 110468396
Inflammation 13.40 12.81 16 26550 193222 110369511
Condition aggravated 13.20 12.81 113 26453 734723 109828010
Lip swelling 13.11 12.81 34 26532 50633 110512100
Infection 13.04 12.81 44 26522 362156 110200577
Diabetic retinopathy 13.03 12.81 9 26557 3555 110559178
Mental status changes 12.93 12.81 44 26522 76078 110486655
Concomitant disease progression 12.93 12.81 9 26557 3601 110559132

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
ATC C09BB13 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:50266 prodrug
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
FDA PE N0000178477 Decreased Blood Pressure

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs
captoprilcilazaprildelaprilenalaprilfosinoprilimidaprillisinoprilmoexiprilperindoprilquinaprilramiprilspirapril show all 15 →
C09BA ACE inhibitors and diuretics 11 drugs
captoprilcilazaprildelaprilenalaprilfosinoprillisinoprilmoexiprilperindoprilquinaprilramiprilzofenopril
C09BB ACE inhibitors and calcium channel blockers 13 drugs
amlodipinedelaprilenalaprilfelodipinelercanidipinelisinoprilmanidipinenitrendipineperindoprilramipriltrandolaprilverapamil show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Acute scleroderma renal crisis off-label use 236503001
Diastolic heart failure off-label use 418304008 DOID:9775
Hypertension due to Scleroderma off-label use
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Azotemia contraindication 445009001
Intestinal Angioedema contraindication
Head and Neck Angioedema contraindication
Hemodialysis with High-Flux Membrane contraindication
Severe Aortic Valve Stenosis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

ProductApplicantIngredients
Cardalis Ceva Sante Animale 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.9 acidic
pKa2 5.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.70 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.77 CHEMBL

External reference:

IDSource
4020817 VUID
N0000148336 NUI
D00620 KEGG_DRUG
86541-74-4 SECONDARY_CAS_RN
1546196 RXNORM
C0053091 UMLSCUI
CHEBI:3011 CHEBI
CHEMBL838 ChEMBL_ID
CHEMBL1694 ChEMBL_ID
DB00542 DRUGBANK_ID
C044946 MESH_SUPPLEMENTAL_RECORD_UI
5362124 PUBCHEM_CID
6374 IUPHAR_LIGAND_ID
6129 INN_ID
UDM7Q7QWP8 UNII
DB14125 DRUGBANK_ID
4251 MMSL
48720 MMSL
d00730 MMSL
C0105523 UMLSCUI
CHEMBL1192519 ChEMBL_ID
86541-78-8 SECONDARY_CAS_RN
5463984 PUBCHEM_CID
6375 IUPHAR_LIGAND_ID
6128 INN_ID
4020025 VANDF
4020817 VANDF
C052133 MESH_SUPPLEMENTAL_RECORD_UI
JRM708L703 UNII
003597 NDDF
003598 NDDF
108572003 SNOMEDCT_US
108573008 SNOMEDCT_US
372511001 SNOMEDCT_US
CHEBI:88200 CHEBI
JRM708L703 INXIGHT DRUGS
UDM7Q7QWP8 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0364 CAPSULE 20 mg ORAL NDA 29 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0379 CAPSULE 40 mg ORAL NDA 29 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0405 CAPSULE 10 mg ORAL NDA 29 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0406 CAPSULE 20 mg ORAL NDA 29 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0227 TABLET 10 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0227 TABLET 10 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0228 TABLET 20 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0228 TABLET 20 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0229 TABLET 20 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0229 TABLET 20 mg ORAL NDA authorized generic 23 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-554 TABLET 20 mg ORAL ANDA 13 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-561 TABLET, FILM COATED 40 mg ORAL ANDA 13 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-566 TABLET 10 mg ORAL ANDA 13 sections
BENAZEPRIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-259 TABLET 20 mg ORAL ANDA 13 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-280 TABLET 10 mg ORAL ANDA 12 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-327 TABLET, FILM COATED 20 mg ORAL ANDA 19 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-612 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Amlobenz HUMAN PRESCRIPTION DRUG LABEL 2 21695-866 CAPSULE 10 mg ORAL ANDA 27 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-877 TABLET, FILM COATED 40 mg ORAL ANDA 19 sections
Amlobenz HUMAN PRESCRIPTION DRUG LABEL 2 21695-916 CAPSULE 20 mg ORAL ANDA 27 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-749 TABLET 5 mg ORAL ANDA 23 sections
Benazepril Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-750 TABLET 10 mg ORAL ANDA 23 sections